UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Huaigeng Xu, MD, PhD

Title(s)Postdoctoral Scholar, Urology
SchoolSchool of Medicine
ORCID ORCID Icon0000-0002-4415-1287 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    CiRA, Kyoto University, Kyoto, JapanPhD03/2019Medicine
    Tsuruga Municipal Hospital, Tsuruga, Fukui, Japan03/2015Residency
    Osaka Medical College, Takatsuki, Osaka, JapanMD03/2013Medicine
    Collapse Awards and Honors
    Inoue Foundation for Science 2020Inoue Research Award for Young Scientists
    CiRA 2019 International Symposium2019Best Poster Presentation Award
    CiRA, Kyoto University2019CiRA Encouragement Award
    2018 CiRA Retreat 20182nd Best Oral Presentation Award
    2017 CiRA Retreat2017Best Poster Presentation Award

    Collapse Overview 
    Collapse Overview
    Huaigeng Xu was born in China and grew up in Japan.
    He obtained his MD and PhD in Japan and recently started working at UCSF from March 2020.

    During his PhD, he generated low immunogenicity iPS cells by disrupting HLA genes via CRISPR-Cas9 based genome-editing (Xu et al, Cell Stem Cell, 2019).
    During this work, he learned iPS cell culture and differentiation to blood cells, CRISPR-Cas9 genome editing, immunology (e.g. T cells, NK cells and immune rejection) and basic mouse experiments.

    His personal interest is aging, and his ultimate goal in the future is to solve age-related health problems and manage his longevity.
    He speaks both Japanese and Chinese, and he is willing to interact with a lot of people.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, Hozumi H, Miura Y, Yang LF, Iwasaki M, Wang XH, Waller MA, Shirai N, Abe YO, Fujita Y, Watanabe K, Kagita A, Iwabuchi KA, Yasuda M, Xu H, Noda T, Komano J, Sakurai H, Inukai N, Hotta A. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun. 2020 Mar 13; 11(1):1334. PMID: 32170079.
      View in: PubMed
    2. Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, Akasaka M, Nakamura S, Higashi N, Xu H, Matsumoto T, Fujio K, Manz MG, Hotta A, Takizawa H, Eto K, Sugimoto N. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020 01 14; 14(1):49-59. PMID: 31883921.
      View in: PubMed
    3. Morisaka H, Yoshimi K, Okuzaki Y, Gee P, Kunihiro Y, Sonpho E, Xu H, Sasakawa N, Naito Y, Nakada S, Yamamoto T, Sano S, Hotta A, Takeda J, Mashimo T. CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun. 2019 12 06; 10(1):5302. PMID: 31811138.
      View in: PubMed
    4. Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S, Hotta A. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019 04 04; 24(4):566-578.e7. PMID: 30853558.
      View in: PubMed
    5. Zhitnyuk Y, Gee P, Lung MSY, Sasakawa N, Xu H, Saito H, Hotta A. Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochem Biophys Res Commun. 2018 11 10; 505(4):1097-1102. PMID: 30316514.
      View in: PubMed
    6. Ishida K, Xu H, Sasakawa N, Lung MSY, Kudryashev JA, Gee P, Hotta A. Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells. Sci Rep. 2018 01 10; 8(1):310. PMID: 29321585.
      View in: PubMed
    7. Gee P, Xu H, Hotta A. Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. Stem Cells Int. 2017; 2017:8765154. PMID: 28607562.
      View in: PubMed